These are two consecutive entries on The Guardian's live blog, but - is it the same vaccine exactly? Anyway, that seems a downer for the countries dependent on this, and also for China itself.
A vaccine developed by China’s Sinovac showed “general efficacy” of 50.4% in a late-stage trial in Brazil, researchers have said; barely enough for regulatory approval and far short of earlier indications. The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world’s second-deadliest outbreak. The letdown after a more promising partial data disclosure last week may also contribute to criticism that vaccines developed by Chinese manufacturers are not subject to the same public scrutiny as US and European alternatives.
.
.
.
Indonesia will start a mass vaccination campaign on Wednesday, with the president,
Joko Widodo, to receive the first shot. The ambitious vaccination drive is being launched amid record deaths in one of Asia’s most stubborn epidemics. The campaign aims to inoculate 181.5 million people, the first of whom will receive the CoronaVac vaccine from China’s Sinovac Biotech, which Indonesia authorised for emergency use on Monday, with an efficacy rate of 65.3%. The president, who is known as Jokowi, will be given a CoronaVac shot on Wednesday morning, his office said, in a sign of the priority placed on immunisation in a country that has done far less than its south-east Asian neighbours to track and contain the virus. The minster of health,
Budi Gunadi Sadikin, told parliament on Tuesday that nearly 1.5 million medical workers would be inoculated by February, followed by public servants and the general population within 15 months.
Edit: I found this:
https://www.bloomberg.com/news/arti...ing-global-with-four-different-efficacy-rates
Openness is key. Maybe a tad difficult for this particular country?